Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eleanor Dunlap

Nurse Practitioner, Acute Care Baltimore, MD Nurse Practitioner

NPI 1265857205 CMS profile 11178504

22 S Greene St, Baltimore, MD 21201

Open in the dashboard

General payments

$10,658

143 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eleanor Dunlap of Baltimore, MD is reported in the CMS Open Payments database as having received $10,658 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,804 44
2024 General $841 16
2023 General $3,033 33
2022 General $1,077 31
2021 General $903 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eleanor Dunlap
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Eleanor Dunlap were reported at $4,804. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Eleanor Dunlap Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $903 $123 $38–$327 $132
2022 $1,077 $130 $44–$369 $149
2023 $3,033 $144 $49–$410 $160
2024 $841 $146 $48–$433 $164
2025 $4,804 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Smith+Nephew, Inc. $2,187 63 payments
  2. Organogenesis Inc. $2,037 29 payments
  3. Integra LifeSciences Corporation $1,998 2 payments
  4. Stryker Corporation $1,320 1 payment
  5. ProgenaCare Global, LLC $522 11 payments
  6. Boston Scientific Corporation $474 7 payments
  7. Baxter Healthcare $365 6 payments
  8. Tactile Systems Technology Inc $352 5 payments
  9. KCI USA, Inc $333 6 payments
  10. Silk Road Medical, Inc. $230 2 payments
  11. Other $841 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,238 139 payments
  2. Consulting Fee $3,300 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,120 2 payments
Products named General payments · program years 2021–2025
  1. SURGIMEND $1,980 1 payment
  2. CODMAN CERTAS $1,980 1 payment
  3. CT THROMBECTOMY SYSTEM KIT $1,320 1 payment
  4. FLOWTRIEVER CATHETER, S $1,320 1 payment
  5. APLIGRAF $1,312 5 payments
  6. GRAFIX PL Other Advanced Wound Management $1,229 39 payments
  7. General - Vascular Intervention $474 7 payments
  8. Puraply $444 16 payments
  9. GRAFIX PL Other Advanced Wound Management $415 6 payments
  10. STRAVIX PL $385 4 payments
  11. Other $5,549 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

104

Median for Nurse Practitioner: 389

Drug cost

$27,124

Median for Nurse Practitioner: $21,885

Branded share of claims

72.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $16,187
Xarelto Rivaroxaban Brand 16 $10,303
Clopidogrel Clopidogrel Bisulfate Brand 37 $313
Duloxetine Hcl Generic 17 $175
Atorvastatin Calcium Generic 12 $146

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$520,968

Medicare's payments for the services billed

Medicare patients

171

Average age 69

Services billed

1,510

90 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Ischemic heart disease 54%
Arthritis 54%
Chronic kidney disease 44%
Heart failure 39%
Depression 31%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record